Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer

Journal of Clinical Oncology

Volumn 27, Issue 28, 2009, Pages 4787-4792

  Socinski, Mark A ^a   Smit, Egbert F ^a   Lorigan, Paul ^a   Konduri, Kartik ^a   Reck, Martin ^a   Szczesna, Aleksandra ^a   Blakely, Johnetta ^a   Serwatowski, Piotr ^a   Karaseva, Nina A ^a   Ciuleanu, Tudor ^a   Jassem, Jacek ^a   Dediu, Mircea ^a   Hong, Shengyan ^a   Visseren Grul, Carla ^a   Hanauske, Axel Rainer ^a   Obasaju, Coleman K ^a   Guba, Susan C ^a   Thatcher, Nick ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CARBOPLATIN PLUS ETOPOSIDE; CARBOPLATIN PLUS PEMETREXED; CYANOCOBALAMIN; DEXAMETHASONE; ERYTHROPOIETIN; FOLIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG; CARBOPLATIN; DRUG DERIVATIVE; ETOPOSIDE; GLUTAMIC ACID DERIVATIVE; GUANINE; PEMETREXED;

ADULT; AGED; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BRAIN HEMORRHAGE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVULSION; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPONATREMIA; KIDNEY FAILURE; LEUKOPENIA; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SIDE EFFECT; SUDDEN DEATH; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; CHEMICALLY INDUCED DISORDER; KAPLAN MEIER METHOD; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME;

AGED; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; ETOPOSIDE; FATIGUE; FEMALE; GLUTAMATES; GUANINE; HUMANS; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NAUSEA; NEUTROPENIA; SMALL CELL LUNG CARCINOMA; TREATMENT OUTCOME;

EID: 70350435454     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.23.1548     Document Type: Article

References (28)

1. Govindan R, Page N, Morgensztern D, et al: Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 24:4539-4544, 2006
2. American Cancer Society: Cancer reference information: All about lung cancer-small cell, November 2008 update. http://www.cancer.org/ docroot/CRI/CRI-2-1x.asp?rnav=criov&dt=15
3. Gillenwater H, Socinski MA: Extensive stage small cell lung cancer, in Detterbeck FC, Rivera MP, Socinski MA, et al (eds): Diagnosis and Treatment of Lung Cancer: An Evidence-Based Guide for the Practicing Clinician. Philadelphia, PA, Saunders, 2001, pp 360-376
4. Kosmidis PA, Samantas E, Fountzilas G, et al: Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: A randomized phase III study. Hellenic Cooperative Oncology Group for Lung Cancer Trials. Semin Oncol 21:23-30, 1994
5. Lassen U, Kristjansen PE, Osterlind K, et al: Superiority of cisplatin or carboplatin in combination with teniposide and vincristine in the induction chemotherapy of small-cell lung cancer. A randomized trial with 5 years follow up. Ann Oncol 7:365-371, 1996
6. Socinski MA, Weissman C, Hart LL, et al: Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer. J Clin Oncol 24:4840-4847, 2006
7. Socinski MA, Raju RN, Neubauer M, et al: Pemetrexed in relapsed small-cell lung cancer and the impact of shortened vitamin supplementation lead-in time: Results of a phase II trial. J Thorac Oncol 3:1308-1316, 2008
8. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
9. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982
10. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41, 1976
11. Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31:103-115, 1975
12. Ozer H, Armitage JO, Bennett CL, et al: 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 18:3558-3585, 2000
13. National Cancer Institute, Cancer Therapy Evaluation Program, Common terminology criteria for adverse events (CTCAE) v3.0. http://ctep.info.nih.gov/ protocolDevelopment/electronic-applications/ctc.htm
14. Cox DR, Snell EJ: Analysis of Binary Data (ed 2). London, United Kingdom, Chapman & Hall, 1989
15. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
16. Freidlin B, Korn EL: Monitoring for lack of benefit: A critical component of a randomized clinical trial. J Clin Oncol 27:629-633, 2009
17. Jalal S, Ansari R, Govindan R, et al: Pemetrexed in second line and beyond small cell lung cancer: A Hoosier Oncology Group phase II study. J Thorac Oncol 4:93-96, 2009
18. Grønberg BH, Bremnes RM, Aasebø U, et al: A prospective phase II study: High-dose pemetrexed as second-line chemotherapy in small-cell lung cancer. Lung Cancer 63:88-93, 2009
19. Jett JR, Bernath AM, Foster NR, et al: Phase II trial of pemetrexed (P) and carboplatin (C) in previously untreated extensive stage disease small cell lung cancer (ED-SCLC): A NCCTG study. J Clin Oncol 26:440s, 2008 (suppl; abstr 8066)
20. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21: 2636-2644, 2003
21. Scagliotti GV, Parikh P, von Pawel J, et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapynaive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543-3551, 2008
22. Hanna N, Shepherd FA, Fossella FV, et al: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589-1597, 2004
23. Schultz RM, Chen VJ, Bewley JR, et al: Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs. Semin Oncol 26:68-73, 1999
24. Sigmond J, Backus HH, Wouters D, et al: Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression. Biochem Pharmacol 66:431-438, 2003
25. Giovannetti E, Mey V, Nannizzi S, et al: Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol 68:110-118, 2005
26. Ceppi P, Volante M, Saviozzi S, et al: Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 107: 1589-1596, 2006
27. Scagliotti G, Kaiser C, Biesma B, et al: Correlations of biomarker expression and clinical outcome in a large phase III trial of pemetrexed plus cisplatin or gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). J Thorac Oncol 2:S375, 2007 (suppl 4; abstr C6-01)
28. Ceppi P, Volante M, Ferrero A, et al: Thymidylate synthase expression in gastroenteropancreatic and pulmonary neuroendocrine tumors. Clin Cancer Res 14:1059-1064, 2008